Prospects and Limits of Pharmacogenetics: The Thiopurine Methyl Transferase (TPMT) Experience

By van Aken J.   Schmedders M.   Feuerstein G.   Kollek R.  

American Journal of PharmacoGenomics, Vol. 3, Iss. 3, 2003-01 ,pp. : 149-155

Adis International

Access to resources Recommend Favorite

Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity

By Reuther Lene   Vainer Ben   Sonne Jesper   Larsen Niels-Erik  

European Journal of Clinical Pharmacology, Vol. 59, Iss. 11, 2004-01 ,pp. : 797-801

Springer Publishing Company

Access to resources Recommend Favorite

Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?

By Higgs Jenny E   Payne Katherine   Roberts Chris   Newman William G  

Pharmacogenomics, Vol. 11, Iss. 2, 2010-02 ,pp. : 177-188

Future Medicine

Access to resources Recommend Favorite

Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 6, Iss. 1, 2008-03 ,pp. : 33-44

Bentham Science Publishers

Access to resources Recommend Favorite

TPMT activity predicts azathioprine toxicity

By  

Inpharma, Vol. 1, Iss. 1361, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite